Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Depreciation & Amortization (CF): 2022-2025

Historic Depreciation & Amortization (CF) for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $200,000.

  • Taysha Gene Therapies' Depreciation & Amortization (CF) fell 33.33% to $200,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 16.36%. This contributed to the annual value of $1.2 million for FY2024, which is 11.07% down from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Depreciation & Amortization (CF) is $200,000, which was down 33.33% from $300,000 recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year Depreciation & Amortization (CF) high stood at $400,000 for Q2 2023, and its period low was $200,000 during Q3 2025.
  • For the 3-year period, Taysha Gene Therapies' Depreciation & Amortization (CF) averaged around $314,091, with its median value being $300,000 (2025).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 33.33% in 2023, then slumped by 33.33% in 2025.
  • Taysha Gene Therapies' Depreciation & Amortization (CF) (Quarterly) stood at $390,000 in 2022, then grew by 1.28% to $395,000 in 2023, then declined by 23.04% to $304,000 in 2024, then tumbled by 33.33% to $200,000 in 2025.
  • Its Depreciation & Amortization (CF) was $200,000 in Q3 2025, compared to $300,000 in Q2 2025 and $300,000 in Q1 2025.